Influenza Reagent
INFLUENZA VIRUS INFECTIOUS NYMC X-161B
NIBSC code: 06/242
Instructions for use
(Version 3.0, Dated 09/07/2021)

1. INTENDED USE
Reagent 06/242 is prepared from NYMC X-161B which was processed for freeze drying in 250µl volumes as described by Campbell, PJ, Journal of Biological Standardisation, 1974, 2,249-267. The known passage history of NYMC X-161B is attached.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
No unitage is assigned to this material

4. CONTENTS
Country of origin of biological material: United Kingdom.
Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from embryonated hen’s eggs

5. STORAGE
Store in the dark at -20°C
Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

7. USE OF MATERIAL
Reconstitute the contents of one ampoule of reagent with 250µl of sterile distilled water. Leave for a minimum of 5 minutes before use to allow for complete solution of freeze-dried material. A range of dilutions (e.g. 10⁻² to 10⁻⁷) should be made in a suitable medium for initial cultivation.

8. STABILITY
No stability data is available for this material

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES
NA

10. ACKNOWLEDGEMENTS
NA

11. FURTHER INFORMATION
Further information can be obtained as follows:
This material: enquiries@nibsc.org

WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance:</td>
<td></td>
</tr>
<tr>
<td>Freezeen dried powder</td>
<td>Corrosive: No</td>
</tr>
<tr>
<td>Stable:</td>
<td>Oxidising: No</td>
</tr>
<tr>
<td>Hygroscopic:</td>
<td>Irritant: No</td>
</tr>
<tr>
<td>Flammable:</td>
<td>Handling: See caution, Section 2</td>
</tr>
<tr>
<td>Other (specify):</td>
<td>Live influenza virus</td>
</tr>
</tbody>
</table>

**Toxicological properties**

- Effects of inhalation: Likelihood of influenza virus infection
- Effects of ingestion: Not established, avoid ingestion
- Effects of skin absorption: Not established, avoid contact with skin

**Suggested First Aid**

- Inhalation: Seek medical advice
- Ingestion: Seek medical advice
- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash thoroughly with water.

**Action on Spillage and Method of Disposal**

- Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water.
- Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.
Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

| Country of origin for customs purposes*: United Kingdom |
| _____________________________________________________ |
| * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying. |

| Net weight: 0.25 g |
| Toxicity Statement: Non-toxic |
| Veterinary certificate or other statement if applicable. |
| Attached: No |

### Derivation of NYMC X-161B (Post mixed infection)

<table>
<thead>
<tr>
<th>Passage</th>
<th>Lot</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1 – E7</td>
<td></td>
<td>NYMC, New York, USA</td>
</tr>
<tr>
<td>E8</td>
<td>E#5652</td>
<td>NYMC, New York, USA</td>
</tr>
<tr>
<td>E9</td>
<td>24980</td>
<td>NIBSC, Hertfordshire, UK</td>
</tr>
</tbody>
</table>

### Derivation of NYMC X-161B
A/Wisconsin/67/2005 (H3N2) with A/PR/8/34 M and NP
High Yield A Reassortant

Exper. # 4606 II (2/7/06)
A/Wisconsin/67/2005 (CDC#2005756250) recd. from CDC 2/3/06
SpfCK 3E3 (1/06/06) HA 1:64

Post-reassortant

1 $10^1$ + $10^5$

HA—C*1:4096

1 $10^1 (e8)$ + A/PR/8/34 N1 antisera (as) A/PR/8/34 antisera (as)

HA—C 1:128

2 $10^1$ + A/PR/8/34 N1 antisera (as) A/PR/8/34 HANA antibodies (ab)

HA—C 1:256

(ab)

3 $10^1$ + A/PR/8/34 N1 antisera (as) A/PR/8/34 HANA antibodies (ab)

HA—C 1:256

4 $10^1$

HA—C 1:1024

5 $10^1$

HA—C 1:256

6 $10^1$

HA—C 1:128

7 $10^7$

HA—C 1:512

8 $10^4$

HA—C 1:1706 5

(E#5652—NYMC archive)

→→→NYMC X-161B sent to CDC 4/18/06
Appendix (derivation received from NYMC)

*C, chicken red blood cells
HA and NA identified as A/Wisconsin/67/2005 serologically by HI and NI tests and by RT-PCR/RFLP analysis of HA and NA genes.
M and NP genes identified as A/PR/8/34 by RT-PCR/RFLP analysis.
SPAFAS eggs used exclusively for all passages.